Compare Abeona Therapeutics Inc (ABEO) vs BlackBerry Limited (BB) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

BlackBerry (BB) trades at $11.10, down 3.56% on the day but remains in a strong uptrend, having more than tripled year-to-date. The stock is technically bullish with recent earnings beats and improved guidance fueling optimism. Revenue growth is returning, with Q1 2026 results showing a profit turnaround, though valuation multiples remain elevated. Positive sentiment is driven by QNX software growth and the launch of leveraged ETFs tied to the stock.

Outlook is cautiously optimistic as execution on QNX and cybersecurity growth must justify high valuations. Key risks include competitive pressures and the need to sustain profitability. Analysts are mostly neutral with a consensus price target of $10.50, suggesting limited near-term upside from current levels amid rich pricing.